Adverse event | Sorafenib group (n = 48) | TACE + sorafenib group (n = 56) | ||||||
---|---|---|---|---|---|---|---|---|
Grade I | Grade II | Grade III | Grade IV | Grade I | Grade II | Grade III | Grade IV | |
Hand-foot skin reactions, n (%) | 25 (44.64%) | 8 (14.29%) | 3 (5.36%) | 0 | 24 (42.86%) | 3 (5.36%) | 3 (5.36%) | 0 |
Vomiting, n (%) | 19 (33.93%) | 5 (8.93%) | 3 (5.36%) | 0 | 26 (46.43%) | 4 (7.14%) | 1 (1.79%) | 0 |
Diarrhea, n (%) | 21 (37.50%) | 4 (7.14%) | 2 (3.57%) | 0 | 23 (41.07%) | 1 (1.79%) | 1 (1.79%) | 0 |
Fatigue, n (%) | 10 (17.86%) | 2 (3.57%) | 0 | 0 | 8 (14.29%) | 4 (7.14%) | 0 | 0 |
Hypertension, n (%) | 19 (33.93%) | 3 (5.36%) | 0 | 0 | 10 (17.86%) | 2 (3.57%) | 1 (1.79%) | 0 |
Leucopenia, n (%) | 5 (8.93%) | 2 (3.57%) | 0 | 0 | 4 (7.14%) | 0 | 1 (1.79%) | 0 |
Anemia, n (%) | 5 (8.93%) | 2 (3.57%) | 0 | 0 | 4 (7.14%) | 1 (1.79%) | 2 (3.57%) | 0 |
Thrombocytopenia, n (%) | 3 (5.36%) | 2 (3.57%) | 2 (3.57%) | 0 | 3 (5.36%) | 4 (7.14%) | 1 (1.79%) | 0 |
Alopecia, n (%) | 2 (3.57%) | 1 (1.79%) | 0 | 0 | 3 (5.36%) | 0 | 1 (1.79%) | 0 |
Gastrointestinal hemorrhage, n (%) | 0 | 0 | 4 (7.14%) | 0 | 2 (3.57%) | 1 (1.79%) | 2 (3.57%) | 0 |
Hepatic encephalopathy, n (%) | 2 (1.79%) | 1 (1.79%) |